{
    "clinical_study": {
        "@rank": "163007", 
        "acronym": "DOLORES", 
        "arm_group": [
            {
                "arm_group_label": "Rotigotine", 
                "arm_group_type": "Experimental", 
                "description": "Rotigotine Transdermal Patches"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo Transdermal Patches"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is being conducted to compare the impact of Rotigotine and Placebo on Chronic\n      Pain associated with Parkinson's Disease among patients with advanced stages of the disease."
        }, 
        "brief_title": "Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Advanced Idiopathic Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient has advanced idiopathic Parkinson's Disease associated chronic pain assessed\n             by a Likert Pain Scale\n\n          -  Patient is taking Levodopa with a stable daily dose of at least 200 mg for at least\n             21 days prior to start\n\n          -  Hoehn and Yahr stage score of II to IV\n\n          -  Mini-Mental State Examination (MMSE) score \u2265 25\n\n          -  If an antidepressant drug is taken, the dose must be stable for at least 21 days\n\n        Exclusion Criteria:\n\n          -  Therapy with a Dopamine Agonist within 21 days prior to start\n\n          -  Discontinuation from previous Dopamine Agonist Therapy due to lack of efficacy\n\n          -  Therapy with Dopamine-modulating substances 21 days prior to start\n\n          -  Therapy with analgesics for the treatment for pain, unless the dose has been stable\n\n          -  Chronic alcohol or drug abuse\n\n          -  Medical or psychiatric condition that, in the opinion of the investigator, could\n             jeopardize or would compromise the patient's ability to participate in this study\n\n          -  Hypersensitivity to any components of the Investigational Medicinal Product (IMP) or\n             comparative drugs\n\n          -  Atypical Parkinson's Disease Syndrome due to drugs\n\n          -  History of deep brain stimulation\n\n          -  Significant skin disease that would make transdermal drug use inappropriate\n\n          -  Electroconvulsive therapy within 12 weeks prior to start\n\n          -  Evidence of an Impulse Control Disorder\n\n          -  Previous diagnosis of severe Restless Legs Syndrome\n\n          -  Chronic Migraine\n\n          -  Severe Depression\n\n          -  Symptomatic Orthostatic Hypotension"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "68", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01744496", 
            "org_study_id": "PD0004", 
            "secondary_id": "2012-002608-42"
        }, 
        "intervention": [
            {
                "arm_group_label": "Rotigotine", 
                "description": "Patches will contain 4 mg / 24 h (20 cm^2), 6 mg/ 24 h (30 cm^2), or 8 mg /24 h (40 cm^2) of Rotigotine. Application of study medication starts at the Baseline Visit. Rotigotine will be administered once daily starting at 4 mg / 24 h. Doses will then be up-titrated in weekly increments of 2 mg / 24 h until optimal or maximum dose (16 mg / 24 h) is reached and the Maintenance Period can be started. The duration of the Titration Period will vary from 1 to 7 weeks \u00b1 3 days. The Maintenance Period will last 12 weeks \u00b1 5 days. Thereafter, during the De-escalation Period, the dose of study medication will be decreased by 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.", 
                "intervention_name": "Rotigotine", 
                "intervention_type": "Drug", 
                "other_name": "(6S)-6-propyl-[2 (2 thienyl)ethyl]amino-5,6,7,8-tetrahydro-1-naphthalenol"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo patches match the size of active patches 20 cm^2, 30 cm^2, or 40 cm^2 and will contain Placebo. Application of Placebo patches starts at the Baseline Visit. Placebo patches will be administered once daily starting with the equivalent of 4 mg / 24 h. Doses will then be up-titrated in weekly equivalents to 2 mg / 24 h until either optimal dose or maximum dose is reached. The maximum dose is the equivalent to 16 mg / 24 h. The duration of the Titration Period will vary from 1 to 7 weeks. The Maintenance Period will last 12 weeks \u00b1 5 days. During the De-escalation Period, the dose of Placebo will be decreased by the equivalent to 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "N 0437"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Parkinson's Disease", 
            "Rotigotine", 
            "Chronic Pain", 
            "Nonmotor symptoms"
        ], 
        "lastchanged_date": "February 6, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Gilbert", 
                        "country": "United States", 
                        "state": "Arizona"
                    }, 
                    "name": "2113"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sunnyvale", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "2120"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "2109"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }, 
                    "name": "2107"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky"
                    }, 
                    "name": "2102"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Advance", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "2118"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "2117"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tulsa", 
                        "country": "United States", 
                        "state": "Oklahoma"
                    }, 
                    "name": "2103"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roanoke", 
                        "country": "United States", 
                        "state": "Virginia"
                    }, 
                    "name": "2101"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin"
                    }, 
                    "name": "2104"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gera", 
                        "country": "Germany"
                    }, 
                    "name": "1204"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gdansk", 
                        "country": "Poland"
                    }, 
                    "name": "1607"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Krakow", 
                        "country": "Poland"
                    }, 
                    "name": "1603"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Olsztyn", 
                        "country": "Poland"
                    }, 
                    "name": "1609"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bratislava", 
                        "country": "Slovakia"
                    }, 
                    "name": "1804"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dubnica Nad Vahom", 
                        "country": "Slovakia"
                    }, 
                    "name": "1805"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany", 
                "Hungary", 
                "Korea, Republic of", 
                "Poland", 
                "Slovakia"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 2-Arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain", 
        "overall_official": {
            "affiliation": "+1 877 822 9493 (UCB)", 
            "last_name": "UCB Clinical Trial Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Argentina: Ministry of Health", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines", 
                "Hungary: National Institute of Pharmacy", 
                "Mexico: Federal Commission for Protection Against Health Risks", 
                "Poland: Ministry of Health", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Slovakia: State Institute for Drug Control", 
                "Ukraine: Ministry of Health", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "An 11-Point Likert Scale will be used to assess patients' average daily pain.", 
            "measure": "Change from Baseline to the End of the Maintenance Period in pain severity assessed using an 11-point Likert Pain Scale", 
            "safety_issue": "No", 
            "time_frame": "Baseline (Visit 2) until End of the Maintenance Period (Maintenance Period lasts 12 weeks \u00b1 5 days after an up to 7 weeks Titration Period)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01744496"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Responders are defined as patients experiencing a 2-Point ore more Reduction on an 11-Point Likert Pain Scale from Baseline to the End of the Maintenance Period.", 
                "measure": "Percentage of Responders at the End of the Maintenance Period", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Visit 2) until End of the Maintenance Period (Maintenance Period lasts 12 weeks \u00b1 5 days after up to 7 weeks Titration Period)"
            }, 
            {
                "measure": "Change from Baseline to the End of the Maintenance Period in the sum score of the 8-Item Parkinson's Disease Questionnaire (PDQ-8)", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Visit 2) until End of the Maintenance Period (Maintenance Period lasts 12 weeks \u00b1 5 days after up to 7 weeks Titration Period)"
            }, 
            {
                "measure": "Change from Baseline to the End of the Maintenance Period in the combined score of the Unified Parkinson's Disease Rating Scale (UPDRS) Parts II (Activities of Daily Living [ADL] subscale) and III (motor subscale)", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Visit 2) until End of the Maintenance Period (Maintenance Period lasts 12 weeks \u00b1 5 days after up to 7 weeks Titration Period)"
            }, 
            {
                "measure": "Change from Baseline to the End of the Maintenance Period in the 7 domain scores of Classification of Pain in Parkinson's Disease", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Visit 2) until End of the Maintenance Period (Maintenance Period lasts 12 weeks \u00b1 5 days after up to 7 weeks Titration Period)"
            }, 
            {
                "measure": "Change from Baseline to the End of the Maintenance Period in the 7-Item Depression subscore of the Hospital Anxiety and Depression Scale (HADS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Visit 2) until End of the Maintenance Period (Maintenance Period lasts 12 weeks \u00b1 5 days after up to 7 weeks Titration Period)"
            }, 
            {
                "measure": "Change from Baseline to the End of the Maintenance Period in the 7-Item Anxiety subscore of the Hospital Anxiety and Depression Scale (HADS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Visit 2) until End of the Maintenance Period (Maintenance Period lasts 12 weeks \u00b1 5 days after up to 7 weeks Titration Period)"
            }
        ], 
        "source": "UCB, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "UCB BIOSCIENCES GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}